Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by Cantor Fitzgerald

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 169.23% from the stock’s current price.

ATNM has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday. Maxim Group raised their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN:ATNM opened at $7.80 on Tuesday. Actinium Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $9.86. The firm has a market capitalization of $232.28 million, a PE ratio of -4.56 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. Analysts forecast that Actinium Pharmaceuticals will post -1.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brandywine Global Investment Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter valued at about $1,033,000. Creative Financial Designs Inc. ADV boosted its position in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares during the period. Finally, Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals during the first quarter worth about $78,000. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.